Literature DB >> 19924110

Valproate and amitriptyline exert common and divergent influences on global and gene promoter-specific chromatin modifications in rat primary astrocytes.

Tatjana Perisic1, Nicole Zimmermann, Thomas Kirmeier, Maria Asmus, Francesca Tuorto, Manfred Uhr, Florian Holsboer, Theo Rein, Jürgen Zschocke.   

Abstract

Aberrant biochemical processes in the brain frequently go along with subtle shifts of the cellular epigenetic profile that might support the pathogenic progression of psychiatric disorders. Although recent reports have implied the ability of certain antidepressants and mood stabilizers to modulate epigenetic parameters, studies comparing the actions of these compounds under the same conditions are lacking. In this study, we screened amitriptyline (AMI), venlafaxine, citalopram, as well as valproic acid (VPA), carbamazepine, and lamotrigine for their potential actions on global and local epigenetic modifications in rat primary astrocytes. Among all drugs, VPA exposure evoked the strongest global chromatin modifications, including histone H3/H4 hyperacetylation, 2MeH3K9 hypomethylation, and DNA demethylation, as determined by western blot and luminometric methylation analysis, respectively. CpG demethylation occurred independently of DNA methyltransferase (DNMT) suppression. Strikingly, AMI also induced slight cytosine demethylation, paralleled by the reduction in DNMT enzymatic activity, without affecting the global histone acetylation status. Locally, VPA-induced chromatin modifications were reflected at the glutamate transporter (GLT-1) promoter as shown by bisulfite sequencing and acetylated histone H4 chromatin immunoprecipitation analysis. Distinct CpG sites in the distal part of the GLT-1 promoter were demethylated and enriched in acetylated histone H4 in response to VPA. For the first time, we could show that these changes were associated with an enhanced transcription of this astrocyte-specific gene. In contrast, AMI failed to stimulate GLT-1 transcription and to alter promoter methylation levels. In conclusion, VPA and AMI globally exerted chromatin-modulating activities using different mechanisms that divergently precipitated at an astroglial gene locus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19924110      PMCID: PMC3055607          DOI: 10.1038/npp.2009.188

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  64 in total

Review 1.  Epigenomics: beyond CpG islands.

Authors:  Melissa J Fazzari; John M Greally
Journal:  Nat Rev Genet       Date:  2004-06       Impact factor: 53.242

2.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

3.  Pharmacological characterization and visualization of the glial serotonin transporter.

Authors:  M Inazu; H Takeda; H Ikoshi; M Sugisawa; Y Uchida; T Matsumiya
Journal:  Neurochem Int       Date:  2001-07       Impact factor: 3.921

4.  Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate.

Authors:  J D Rothstein; M Dykes-Hoberg; C A Pardo; L A Bristol; L Jin; R W Kuncl; Y Kanai; M A Hediger; Y Wang; J P Schielke; D F Welty
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

5.  Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate.

Authors:  B Hassel; E G Iversen; L Gjerstad; E Taubøll
Journal:  J Neurochem       Date:  2001-06       Impact factor: 5.372

6.  Carbamazepine is an inhibitor of histone deacetylases.

Authors:  Andreas S Beutler; SiDe Li; Rebekka Nicol; Martin J Walsh
Journal:  Life Sci       Date:  2005-05-13       Impact factor: 5.037

7.  Increased levels of glutamate in brains from patients with mood disorders.

Authors:  Kenji Hashimoto; Akira Sawa; Masaomi Iyo
Journal:  Biol Psychiatry       Date:  2007-06-15       Impact factor: 13.382

8.  GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes.

Authors:  Michael O Poulter; Lisheng Du; Ian C G Weaver; Miklós Palkovits; Gábor Faludi; Zul Merali; Moshe Szyf; Hymie Anisman
Journal:  Biol Psychiatry       Date:  2008-07-18       Impact factor: 13.382

9.  The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes.

Authors:  Marija Kundakovic; Ying Chen; Alessandro Guidotti; Dennis R Grayson
Journal:  Mol Pharmacol       Date:  2008-11-24       Impact factor: 4.436

Review 10.  The many faces of histone lysine methylation.

Authors:  Monika Lachner; Thomas Jenuwein
Journal:  Curr Opin Cell Biol       Date:  2002-06       Impact factor: 8.382

View more
  45 in total

1.  The role of miRNAs in complex formation and control.

Authors:  Wilson Wen Bin Goh; Hirotaka Oikawa; Judy Chia Ghee Sng; Marek Sergot; Limsoon Wong
Journal:  Bioinformatics       Date:  2011-12-16       Impact factor: 6.937

2.  Valproate prevents dysregulation of spinal glutamate and reduces the development of hypersensitivity in rats after peripheral nerve injury.

Authors:  Masaru Yoshizumi; James C Eisenach; Ken-ichiro Hayashida
Journal:  J Pain       Date:  2013-09-07       Impact factor: 5.820

3.  Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons.

Authors:  Irina A Ionescu; Julien Dine; Yi-Chun Yen; Dominik R Buell; Leonie Herrmann; Florian Holsboer; Matthias Eder; Rainer Landgraf; Ulrike Schmidt
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

4.  Caregiver maltreatment causes altered neuronal DNA methylation in female rodents.

Authors:  Jennifer Blaze; Tania L Roth
Journal:  Dev Psychopathol       Date:  2017-05

Review 5.  Moving pharmacoepigenetics tools for depression toward clinical use.

Authors:  Laura M Hack; Gabriel R Fries; Harris A Eyre; Chad A Bousman; Ajeet B Singh; Joao Quevedo; Vineeth P John; Bernhard T Baune; Boadie W Dunlop
Journal:  J Affect Disord       Date:  2019-02-06       Impact factor: 4.839

6.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

Review 7.  Drugging the pain epigenome.

Authors:  Ellen Niederberger; Eduard Resch; Michael J Parnham; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2017-05-26       Impact factor: 42.937

Review 8.  Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease.

Authors:  Kou Takahashi; Joshua B Foster; Chien-Liang Glenn Lin
Journal:  Cell Mol Life Sci       Date:  2015-06-02       Impact factor: 9.261

Review 9.  Genetic dys-regulation of astrocytic glutamate transporter EAAT2 and its implications in neurological disorders and manganese toxicity.

Authors:  Pratap Karki; Keisha Smith; James Johnson; Michael Aschner; Eunsook Y Lee
Journal:  Neurochem Res       Date:  2014-07-27       Impact factor: 3.996

Review 10.  The role of DNA methylation in the pathophysiology and treatment of bipolar disorder.

Authors:  Gabriel R Fries; Qiongzhen Li; Blake McAlpin; Theo Rein; Consuelo Walss-Bass; Jair C Soares; Joao Quevedo
Journal:  Neurosci Biobehav Rev       Date:  2016-06-18       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.